Cooperative Agreement U01EY034669

Award Date 9/30/22
Completion Date 8/31/25
Dollars Obligated $2.4M
Federal Grant Program
93.867
Assistance Type
Cooperative Agreement
Place of Performance
Pasadena, CA 91103, USA
Similar Awards
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) for $3,120,397 will support the development and characterization of a 3D tissue chip model of the retinal pigment epithelium (RPE)-choroid complex to study the role of genetic risk factors and environmental stressors in the early pathogenesis of age-related macular degeneration (AMD). The research team, led by investigators at the Medical University of South Carolina, will utilize induced pluripotent stem...
This Project Grant award from the National Eye Institute (NEI) of the National Institutes of Health (CFDA 93.867 - Vision Research) provides $658,889 to the University of Rochester to investigate the role of the pro-inflammatory enzyme PLA2G2A/sPLA2-IIA in age-related macular degeneration (AMD). The research aims to utilize human donor eyes, patient-derived induced pluripotent stem cells, and transgenic mouse models to critically evaluate the mutation-independent pathogenic role of PLA2G2A in...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $253,500.00 to the Icahn School of Medicine at Mount Sinai to reconstruct a human blood-retina barrier and perfused vascular system. The goal is to investigate the role of apolipoprotein E (APOE) variants in age-related macular degeneration (AMD), a leading cause of vision loss. The research aims to optimize an in vitro outer blood-retina barrier model, generate isogenic models with different APOE...
This Project Grant award of $620,149 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports a multi-center research program to develop advanced genome editing technologies for modifying critical genetic risk factors associated with age-related macular degeneration (AMD). The research team, led by the University of Iowa, will conduct base editing and prime editing of AMD risk loci in human cells, including induced pluripotent stem...
This federal Project Grant award, provided by the National Eye Institute (CFDA 93.867 Vision Research), supports research at the Whitehead Institute for Biomedical Research to systematically identify and characterize novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration and age-related macular degeneration (AMD). The $173,016 award, effective from Aug 1, 2025 to Jul 31, 2027, will fund a project focused on three primary aims: 1) elucidating the...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $240,713 to investigate the role of the nuclear-encoded humanin isoform MTRNR2L1 in the pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness. The research aims to elucidate whether MTRNR2L1 is a protein-coding gene or long non-coding RNA, and to examine its function in regulating mitochondrial activity and cell survival in retinal pigment epithelial cells under stress...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $638,625 to the University of California, San Diego (UCSD) to develop a "Bruch's Membrane-on-a-Chip" technology for studying the formation of drusen deposits, a key factor in the progression of age-related macular degeneration (AMD). The research aims to investigate the determinants of lipoprotein retention in Bruch's membrane, including the role of apolipoprotein composition and heparan...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides USD 521,572.00 to East Tennessee State University to investigate the role of histone expression in retinal pigment epithelium (RPE) aging and its relationship to age-related macular degeneration (AMD). The research aims to define signatures of histone expression in the aging RPE and determine the cellular effects of histone depletion on RPE homeostasis and AMD progression....
This federal Project Grant award under the National Institutes of Health National Eye Institute's Vision Research program (CFDA 93.867) provides $513,371.00 to The Ohio State University to investigate the mechanisms by which oxidative stress triggers cellular signaling pathways that contribute to age-related macular degeneration (AMD) and other debilitating ocular diseases. The 5-year project aims to elucidate how oxidative stress causes the release of self-DNA into the cytosol, activating the...
The National Eye Institute (NEI) awarded a $291,375 Project Grant (CFDA 93.867 - Vision Research) to the University of Connecticut Health Center to develop a novel mouse model for studying age-related choroidal neovascularization (ARCNV), a key hallmark of wet age-related macular degeneration (AMD). The award, spanning from August 1, 2024 to July 31, 2026, aims to systematically characterize the ARCNV model, which mimics the genetic, environmental, and age-related factors associated with wet...

DECIPHERING THE MECHANISMS ASSOCIATED WITH HIGH-RISK AMD GENOTYPES FOR ARMS2/HTRA1 ANDCOMPLEMENT FACTOR H - PROJECT SUMMARY THIS U01 GRANT APPLICATION IS SUBMITTED IN RESPONSE TO RFA EY-21-002 "AGE-RELATED MACULAR DEGENERATION (AMD) INTEGRATIVE BIOLOGY INITIATIVE", WITH THE GOAL OF DETERMINING IF PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELL (IPSC)-RETINAL PIGMENT EPITHELIUM (RPE) CAN BE USED TO DISCOVER THE UNDERLYING PATHOPHYSIOLOGY OF AMD. STUDIES FROM OUR LABORATORY AS WELL AS THOSE OF OTHERS STRONGLY SUPPORT THE USE OF IPSC-RPE TO UNDERSTAND HOW SPECIFIC SINGLE-NUCLEOTIDE POLYMORPHISMS (SNP) ASSOCIATED WITH HIGH RISK FOR ADVANCED AMD INFLUENCES MULTIPLE BIOLOGICAL PROCESSES IN THE RPE. OUR STUDIES WILL FOCUS ON TWO SNPS WITH THE HIGHEST ODDS RATIO FOR DEVELOPING ADVANCED AMD- AGE-RELATED MACULOPATHY SUSCEPTIBILITY 2/HIGH TEMPERATURE REQUIREMENT A1 (ARMS2/HTRA1) AND COMPLEMENT FACTOR H (CFH). WE WILL USE THE IPSC DEVELOPED BY THE NEI AND THE NEW YORK STEM CELL FOUNDATION (NYSCF) AND DIFFERENTIATE THE PARENT CELLS AND THEIR RECIPROCAL ISOGENIC LINES INTO RPE USING THE PROTOCOL ESTABLISHED IN THE BHARTI LABORATORY. THE PARENT/ISOGENIC LINES PROVIDE AN EXCELLENT MODEL SYSTEM FOR DECIPHERING THE MOLECULAR FACTORS THAT DETERMINE HOW THE PRESENCE OF SNPS IN ONE OR BOTH GENES AFFECT THE RESPONSE TO STRESS. WE WILL TEST THE HYPOTHESIS THAT THE PRESENCE OF HOMOZYGOUS RISK ALLELES FOR EITHER ARMS2/HTRA1 OR CFH, INDEPENDENT AND IN COMBINATION, HAVE A NEGATIVE IMPACT ON THE RPE STRESS RESPONSE. FURTHERMORE, EACH GENETIC RISK PROFILE WILL HAVE A UNIQUE STRESS RESPONSE. OUR PROPOSED STUDIES WILL INTEGRATE CLASSICAL REDUCTIONIST INVESTIGATIONS, COUPLED WITH DISCOVERY-DRIVEN ANALYSES, TO TEST SPECIFIC HYPOTHESES. AIM 1 WILL FOCUS ON DIFFERENTIATING AND CHARACTERIZING IPSC-RPE CELL LINES FROM 10 AMD PATIENTS AND THEIR ISOGENIC LINES. AIM 2 WILL TEST THE HYPOTHESIS THAT THE PRESENCE OF AMD HIGH-RISK SNPS ALTER THE CELLULAR RESPONSE TO STRESS BY PERFORMING LARGE-SCALE QUANTIFICATION OF PROTEINS AND METABOLITES, COUPLED WITH MT FUNCTIONAL ASSAYS. PARENT CELLS AND THEIR ISOGENIC LINES WILL BE COMPARED TO DETERMINE THE IMPACT ON METABOLISM AND THE STRESS RESPONSE IN IPSC-RPE (I) WITH THE CFH HIGH-RISK SNP AND (II) FOR HIGH RISK ARMS2/HTRA1, ALONE OR IN COMBINATION WITH HIGH RISK CFH. THESE STUDIES WILL ADDRESS HOW THE PRESENCE OF SPECIFIC RISK VARIANTS AFFECT RPE EXPOSED TO A PHYSIOLOGICALLY RELEVANT STRESS, AN IMPORTANT GAP IN KNOWLEDGE OF AMD PATHOGENESIS. KNOWLEDGE ABOUT THE MOLECULAR DETAILS HAS THE POTENTIAL TO LEAD TO DEVELOPMENT OF THERAPIES TARGETING THE PRIMARY DEFECT IN A GENETICALLY DEFINED POPULATION OF AMD PATIENTS, WHICH IN TURN, COULD LEAD TO A "PERSONALIZED MEDICINE" APPROACH FOR TREATMENT OF AMD.

Posted 9/20/22